University General Hospital of Thessaloniki "AHEPA"
Welcome,         Profile    Billing    Logout  
 1 Trial 
4 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
garaventa, alberto
HR-NBL2, NCT04221035 / 2019-001068-31: High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

Recruiting
3
800
Europe, RoW
Vincristine, L01CA02, Carboplatin, LO1XA02, Etoposide, L01CB01, Vindesine, L01CA03, Dacarbazine, L01AX04, Ifosfamide, Doxorubicin, L01DB01, Busulfan, L01AB01, Melphalan, L01AA03, Thiotepa, L01AC01, Radiotherapy, Dinutuximab Beta, L01XC16, Cisplatin, L01XA01, Temozolomide 100 MG, Irinotecan, Cyclophosphamid
Gustave Roussy, Cancer Campus, Grand Paris, PHRC, Solving Kids' Cancer Europe, Neuroblastoma UK, , BSPHO, Instituto de Investigación Sanitaria La Fe, Deutsche Krebshilfe
High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy
11/26
11/32
NCT04621201: Genomic Profiles Analysis in Children, Adolescents and Young Adult With Sarcomas

Recruiting
N/A
120
Europe
observation and biopsy
Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna, Associazione Italiana Ematologia Oncologia Pediatrica
Diagnosed or Relapsed/Refractory Sarcomas
12/24
12/26
NCT04253015: A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta

Recruiting
N/A
125
Europe
Data-collection
EusaPharma (UK) Limited, United BioSource, LLC
Neuroblastoma
03/32
06/32
HATZIPANTELIS, EMMANOUEL
HR-NBL2, NCT04221035 / 2019-001068-31: High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

Recruiting
3
800
Europe, RoW
Vincristine, L01CA02, Carboplatin, LO1XA02, Etoposide, L01CB01, Vindesine, L01CA03, Dacarbazine, L01AX04, Ifosfamide, Doxorubicin, L01DB01, Busulfan, L01AB01, Melphalan, L01AA03, Thiotepa, L01AC01, Radiotherapy, Dinutuximab Beta, L01XC16, Cisplatin, L01XA01, Temozolomide 100 MG, Irinotecan, Cyclophosphamid
Gustave Roussy, Cancer Campus, Grand Paris, PHRC, Solving Kids' Cancer Europe, Neuroblastoma UK, , BSPHO, Instituto de Investigación Sanitaria La Fe, Deutsche Krebshilfe
High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy
11/26
11/32

Download Options